humanitarian
Opinion/decision on a Paediatric investigation plan (PIP): Opdualag, nivolumab,relatlimab, decision type: P: decision agreeing on a investigation plan, with or without partial wai…
Opinion/decision on a Paediatric investigation plan (PIP): Tevimbra, tislelizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and…
Reported by EMA What Is New
Read the complete report at EMA What Is New ↗
Verification notice
IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.
3 reports · 2 sources
EMA What Is NewOpinion/decision on a Paediatric investigation plan (PIP): Opdualag, nivolumab,relatlimab, decision type: P: decision agreeing on a investigation plan, with or without partial wai…EMA What Is NewOpinion/decision on a Paediatric investigation plan (PIP): Opdualag, nivolumab,relatlimab, decision type: P: decision agreeing on a investigation plan, with or without partial wai…EMA What Is NewOpinion/decision on a Paediatric investigation plan (PIP): Tevimbra, tislelizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications…3 recorded states
Signal first indexedP2 · 99% quality · 2 sources
Headline updatedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources